ProKidney’s Rilparencel shows promise for CKD patients, with Phase 2 data expected in 2025. Learn why PROK stock is a “Buy” ...

The following is a summary of “Prognostic impact of albuminuria in early-stage chronic kidney disease on cardiovascular outcomes: a cohort study,” published in the January 2025 issue of Cardiology by ...

Ozempic, the blockbuster GLP-1 drug that was originally approved to treat type 2 diabetes, has now also been approved by the ...

The Food and Drug Administration approved Ozempic to be used to lessen the risk of kidney disease from getting worse, end-stage kidney disease and cardiovascular disease-caused death for patients with ...

The Food and Drug Administration has approved Ozempic ® (semaglutide) to reduce the risk of sustained estimated glomerular ...

Chronic kidney disease affects about 37 million adults in the United States and is expected to rise. It is a common ...

Semaglutide is now approved for reducing the risk for worsening kidney disease and cardiovascular death in adults with ...

The US Food and Drug Administration (FDA) has approved Novo Nordisk’s Ozempic (semaglutide) to reduce certain risks ...

Novo Nordisk has announced that the Food and Drug Administration (FDA) has approved semaglutide (Ozempic) to reduce the risk ...